Bergwerk Dov reported option exercise involving 8,370 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD on Nov 15, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Interim Chief Legal Officer
Interim Chief Legal Officer
Filed Nov 17, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
8,370Ordinary Shares
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
20,313Direct
Trade date
Nov 15, 2026Option exercise
Filed
Nov 17, 2026, 4:01 PM ET2-day reporting delay
Accession
0001193125-26-465483Code M · Transaction 402913
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 15, 2026Option exercise8,370$0.00$0Trade 402914
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −2.5%1w ago +0.1%1d ago +4.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on November 15, 2023, with 8,370 vested on each of November 15, 2024, November 15, 2025 and November 15, 2026, and 8,372 vesting on November 15, 2027.